Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: Associations with presenting features, serum interleukin 10 levels, and clinical outcome

Marco Herling, George Z. Rassidakis, L. Jeffrey Medeiros, Theodoros P. Vassilakopoulos, Kay Oliver Kliche, Gianpaolo Nadali, Simonetta Viviani, Valeria Bonfante, Roberto Giardini, Marco Chilosi, Christos Kittas, Alessandro M. Gianni, Gianni Bonadonna, Giovanni Pizzolo, Gerassimos A. Pangalis, Fernando Cabanillas, Andreas H. Sarris

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Purpose: EBV-latent membrane protein-1 (LMP-1) is often expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's lymphoma (cHL), but its clinical significance is controversial. We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome. Experimental Design: Patients were eligible if they had biopsy-proven cHL, were untreated, HIV-1 negative, and had available archival tissue. LMP-1 expression was determined by immunohistochemistry. Results: We identified 577 patients with cHL with a median age of 30 years, 55% of whom were male. LMP-1 was expressed in HRS cells of 124 patients (21%) and was detected in 78 of 461 (17%) patients with nodular sclerosis compared with 44 of 112 (39%) with mixed cellularity (P <0.001 by Fisher's exact test). Patients with tumors with LMP-1-positive HRS cells had higher serum interleukin 10 levels (P = 0.009 by Mann-Whitney test). For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74% compared with 81% for those with LMP-1-negative tumors (P = 0.23, by log-rank test). Overall survival (OS) at 5 years for patients with LMP-1-positive tumors was 90 versus 91% for patients with LMP-1-negative tumors (P = 0.8 by log-rank test). Expression of LMP-1 was not associated with different FFS and OS in patients treated with other regimens or with radiotherapy alone. Conclusions: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients.

Original languageEnglish
Pages (from-to)2114-2120
Number of pages7
JournalClinical Cancer Research
Volume9
Issue number6
Publication statusPublished - Jun 1 2003

Fingerprint

Reed-Sternberg Cells
Hodgkin Disease
Interleukin-10
Membrane Proteins
Serum
Survival
Neoplasms
Epstein-Barr virus EBV-associated membrane antigen
Dacarbazine
Vinblastine
Bleomycin
Sclerosis
Human Herpesvirus 4
Doxorubicin
HIV-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma : Associations with presenting features, serum interleukin 10 levels, and clinical outcome. / Herling, Marco; Rassidakis, George Z.; Medeiros, L. Jeffrey; Vassilakopoulos, Theodoros P.; Kliche, Kay Oliver; Nadali, Gianpaolo; Viviani, Simonetta; Bonfante, Valeria; Giardini, Roberto; Chilosi, Marco; Kittas, Christos; Gianni, Alessandro M.; Bonadonna, Gianni; Pizzolo, Giovanni; Pangalis, Gerassimos A.; Cabanillas, Fernando; Sarris, Andreas H.

In: Clinical Cancer Research, Vol. 9, No. 6, 01.06.2003, p. 2114-2120.

Research output: Contribution to journalArticle

Herling, M, Rassidakis, GZ, Medeiros, LJ, Vassilakopoulos, TP, Kliche, KO, Nadali, G, Viviani, S, Bonfante, V, Giardini, R, Chilosi, M, Kittas, C, Gianni, AM, Bonadonna, G, Pizzolo, G, Pangalis, GA, Cabanillas, F & Sarris, AH 2003, 'Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: Associations with presenting features, serum interleukin 10 levels, and clinical outcome', Clinical Cancer Research, vol. 9, no. 6, pp. 2114-2120.
Herling, Marco ; Rassidakis, George Z. ; Medeiros, L. Jeffrey ; Vassilakopoulos, Theodoros P. ; Kliche, Kay Oliver ; Nadali, Gianpaolo ; Viviani, Simonetta ; Bonfante, Valeria ; Giardini, Roberto ; Chilosi, Marco ; Kittas, Christos ; Gianni, Alessandro M. ; Bonadonna, Gianni ; Pizzolo, Giovanni ; Pangalis, Gerassimos A. ; Cabanillas, Fernando ; Sarris, Andreas H. / Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma : Associations with presenting features, serum interleukin 10 levels, and clinical outcome. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 6. pp. 2114-2120.
@article{a774373aeb6f4e369eacf9d2b7901015,
title = "Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: Associations with presenting features, serum interleukin 10 levels, and clinical outcome",
abstract = "Purpose: EBV-latent membrane protein-1 (LMP-1) is often expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's lymphoma (cHL), but its clinical significance is controversial. We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome. Experimental Design: Patients were eligible if they had biopsy-proven cHL, were untreated, HIV-1 negative, and had available archival tissue. LMP-1 expression was determined by immunohistochemistry. Results: We identified 577 patients with cHL with a median age of 30 years, 55{\%} of whom were male. LMP-1 was expressed in HRS cells of 124 patients (21{\%}) and was detected in 78 of 461 (17{\%}) patients with nodular sclerosis compared with 44 of 112 (39{\%}) with mixed cellularity (P <0.001 by Fisher's exact test). Patients with tumors with LMP-1-positive HRS cells had higher serum interleukin 10 levels (P = 0.009 by Mann-Whitney test). For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74{\%} compared with 81{\%} for those with LMP-1-negative tumors (P = 0.23, by log-rank test). Overall survival (OS) at 5 years for patients with LMP-1-positive tumors was 90 versus 91{\%} for patients with LMP-1-negative tumors (P = 0.8 by log-rank test). Expression of LMP-1 was not associated with different FFS and OS in patients treated with other regimens or with radiotherapy alone. Conclusions: LMP-1 was expressed by HRS cells in 21{\%} of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients.",
author = "Marco Herling and Rassidakis, {George Z.} and Medeiros, {L. Jeffrey} and Vassilakopoulos, {Theodoros P.} and Kliche, {Kay Oliver} and Gianpaolo Nadali and Simonetta Viviani and Valeria Bonfante and Roberto Giardini and Marco Chilosi and Christos Kittas and Gianni, {Alessandro M.} and Gianni Bonadonna and Giovanni Pizzolo and Pangalis, {Gerassimos A.} and Fernando Cabanillas and Sarris, {Andreas H.}",
year = "2003",
month = "6",
day = "1",
language = "English",
volume = "9",
pages = "2114--2120",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma

T2 - Associations with presenting features, serum interleukin 10 levels, and clinical outcome

AU - Herling, Marco

AU - Rassidakis, George Z.

AU - Medeiros, L. Jeffrey

AU - Vassilakopoulos, Theodoros P.

AU - Kliche, Kay Oliver

AU - Nadali, Gianpaolo

AU - Viviani, Simonetta

AU - Bonfante, Valeria

AU - Giardini, Roberto

AU - Chilosi, Marco

AU - Kittas, Christos

AU - Gianni, Alessandro M.

AU - Bonadonna, Gianni

AU - Pizzolo, Giovanni

AU - Pangalis, Gerassimos A.

AU - Cabanillas, Fernando

AU - Sarris, Andreas H.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Purpose: EBV-latent membrane protein-1 (LMP-1) is often expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's lymphoma (cHL), but its clinical significance is controversial. We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome. Experimental Design: Patients were eligible if they had biopsy-proven cHL, were untreated, HIV-1 negative, and had available archival tissue. LMP-1 expression was determined by immunohistochemistry. Results: We identified 577 patients with cHL with a median age of 30 years, 55% of whom were male. LMP-1 was expressed in HRS cells of 124 patients (21%) and was detected in 78 of 461 (17%) patients with nodular sclerosis compared with 44 of 112 (39%) with mixed cellularity (P <0.001 by Fisher's exact test). Patients with tumors with LMP-1-positive HRS cells had higher serum interleukin 10 levels (P = 0.009 by Mann-Whitney test). For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74% compared with 81% for those with LMP-1-negative tumors (P = 0.23, by log-rank test). Overall survival (OS) at 5 years for patients with LMP-1-positive tumors was 90 versus 91% for patients with LMP-1-negative tumors (P = 0.8 by log-rank test). Expression of LMP-1 was not associated with different FFS and OS in patients treated with other regimens or with radiotherapy alone. Conclusions: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients.

AB - Purpose: EBV-latent membrane protein-1 (LMP-1) is often expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's lymphoma (cHL), but its clinical significance is controversial. We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome. Experimental Design: Patients were eligible if they had biopsy-proven cHL, were untreated, HIV-1 negative, and had available archival tissue. LMP-1 expression was determined by immunohistochemistry. Results: We identified 577 patients with cHL with a median age of 30 years, 55% of whom were male. LMP-1 was expressed in HRS cells of 124 patients (21%) and was detected in 78 of 461 (17%) patients with nodular sclerosis compared with 44 of 112 (39%) with mixed cellularity (P <0.001 by Fisher's exact test). Patients with tumors with LMP-1-positive HRS cells had higher serum interleukin 10 levels (P = 0.009 by Mann-Whitney test). For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74% compared with 81% for those with LMP-1-negative tumors (P = 0.23, by log-rank test). Overall survival (OS) at 5 years for patients with LMP-1-positive tumors was 90 versus 91% for patients with LMP-1-negative tumors (P = 0.8 by log-rank test). Expression of LMP-1 was not associated with different FFS and OS in patients treated with other regimens or with radiotherapy alone. Conclusions: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients.

UR - http://www.scopus.com/inward/record.url?scp=0037838706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037838706&partnerID=8YFLogxK

M3 - Article

C2 - 12796376

AN - SCOPUS:0037838706

VL - 9

SP - 2114

EP - 2120

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -